Tumor Conditioning Regimens: An Evolution in Cancer Treatment that Relies on Short-Term Sacrifice for Long-Term Gain

Crossmark: check for updates

Authors

  • Erin Bishop Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
  • Ramani Ramchandran Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA; Department of Pediatrics, Division of Neonatology, Developmental Vascular Biology Program, Children’s Research Institute, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA

DOI:

https://doi.org/10.17140/GOROJ-4-143

Abstract

In this commentary, the authors discuss a new concept for tumor treatment, which is based on observations from published studies and clinical practice protocols. This new treatment regimen, which we coin “Tumor Conditioning Regimens,” abbreviated as TCRs is based on the idea that by conditioning tumors with oxygenation, increasing mutation loads or normalizing vessels, we create a permissive environment for tumor growth in the short-term, which will eventually in the long run benefit tumor regression.

References

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000; 100(1): 57-70. doi: 10.1016/S0092-8674(00)81683-9

Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer microenvironment—clinical implications for treatment strategies. Mol Cancer Res. 2012; 10(10): 1254-1264. doi: 10.1158/1541-7786.MCR-12-0353

Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11(6): 393-410. doi: 10.1038/nrc3064

Howard-Flanders P, Alper T. The sensitivity of microorgan-isms to irradiation under controlled gas conditions. Radiat Res. 1957; 7(5): 518-540.

Overgaard J. Hypoxic modification of radiotherapy in squa-mous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol. 2011; 100(1): 22-32. doi: 10.1016/j.radonc.2011.03.004

Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699-708. doi: 10.1056/NEJMoa1308573

Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblasto-ma. N Engl J Med. 2014; 370(8): 709-722. doi: 10.1056/NEJ-Moa1308345

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8(8): 610-622. doi: 10.1038/nrn2175

Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005; 307(5706): 58-62.

Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK.Vascular normalization by vascular endothelial growth fac-tor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64(11): 3731-3736. doi: 10.1158/0008-5472.CAN-04-0074

Winkler F, Kozin SV, Tong Rt, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor re-sponse to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004. 6(6): 553-563. doi: 10.1016/j.ccr.2004.10.011

Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regu-lates the development, maintenance, and function of induced Gynecol Obstet Res Open J regulatory T cells. J Exp Med. 2009; 206(13): 3015-3129. doi: 10.1084/jem.20090847

Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528): 568-571. doi: 10.1038/nature13954

Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016. 16(2): 121-126. doi: 10.1038/nrc.2016.2

Bouffet E, Larouche V, Campbell BB, et al, Immune checkpoint inhibition for hypermutant glioblastoma multi-forme resulting from germline biallelic mismatch repair defi-ciency. J Clin Oncol. 2016; 34(19): 2206-2211. doi: 10.1200/ JCO.2016.66.6552

Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520(7547): 373-377. doi: 10.1038/nature14292

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2009; 45(2): 228- 247. doi: 10.1016/j.ejca.2008.10.026

Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009; 15(23): 7412- 7420. doi: 10.1158/1078-0432.CCR-09-1624

Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015; 33(31): 3541-3543. doi: 10.1200/JCO.2015.61.6870

Downloads

Published

2017-12-20

How to Cite

Erin Bishop, & Ramani Ramchandran. (2017). Tumor Conditioning Regimens: An Evolution in Cancer Treatment that Relies on Short-Term Sacrifice for Long-Term Gain. Gynecology and Obstetrics Research, 4(2), 41–43. https://doi.org/10.17140/GOROJ-4-143

Issue

Vol. 4 No. 2 (2017): Volume 4 Issue 2 2017

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Gynecology and Obstetrics Research (GOR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.